Tesamorelin / CJC-1295 / Ipamorelin Blend

This blend combines two GHRH analogs, tesamorelin and CJC-1295, with a ghrelin-receptor agonist, ipamorelin, aiming for maximal stimulation of the GH axis. Because tesamorelin and CJC-1295 act at the same receptor, the rationale for combining them centers on differing pharmacokinetics, tesamorelin's shorter action alongside CJC-1295's longer, DAC-extended action, rather than a straightforward additive effect. Evidence for this specific three-peptide combination is limited, and it is discussed primarily in informal research contexts rather than clinical literature. Each individual peptide has its own research base, but the triple combination introduces mechanistic overlap that has not been directly studied. It is not approved for human medical use. Reported benefits include aims to amplify and extend growth-hormone pulse coverage, supports body composition research, associated with recovery support.

Reported ranges run 1,500-3,200 mcg. A low protocol is 1,500 mcg once daily, and a high protocol is 3,200 mcg twice daily. This is reference information, not a dosing recommendation.

Tesamorelin is reported at roughly 25-40 minutes, CJC-1295 without DAC at roughly 30 minutes (or several days with DAC), and ipamorelin at roughly 2 hours, three distinct profiles that add complexity to dosing timing.. That is what sets the dosing frequency, and it is why the timing guidance is ~30 min before bed, empty stomach.

Subcutaneous: into fat, under the skin. Injected subcutaneously, often combined in one syringe; some protocols split dosing across the day given the differing durations of action among the three peptides.

8-12 weeks on, followed by 4-6 weeks off. Because two GHRH analogs act on the same receptor, some researchers question whether combining them adds meaningful benefit over a single GHRH analog paired with a ghrelin-receptor agonist.

Reported side effects include water retention, injection site irritation, headache, increased hunger, joint or muscle discomfort. Evidence level for this compound is moderate evidence.